Damora Therapeutics financials
$20.67+7.27%
Close Oct 20, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$35.0M | -$30.8M |
| Net income | -$24.1M | -$21.3M |
| Net margin | — | — |
| Diluted EPS | $-0.39 | $-0.62 |
| EBITDA | -$35.0M | -$30.8M |
| Operating cash flow | -$21.9M | -$20.6M |
| Free cash flow | -$21.9M | -$20.6M |
| Diluted shares | 61.1M | 34.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $540.5M | $532.9M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $543.6M | $535.4M |
| Total liabilities | $27.6M | $23.8M |
| Shareholders' equity | $516.1M | $510.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology